Soon after, thanks to the advance in high‐throughput sequencing technologies, the first AML genome was reported in 2008 and subsequent studies identified several novel recurrent mutations with pathophysiological, prognostic, or therapeutic relevance such as IDH1, IDH2, or TP53 mutations [8, 9, 10]. This evidence concerns the gene TP53 and acute myeloid leukemia.